Wird geladen...

Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial

Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide early readouts of biological activity and prognosis, offering the possibility for timely response‐guided treatment adjustment. Th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Int J Cancer
Hauptverfasser: Kimbung, Siker, Markholm, Ida, Bjöhle, Judith, Lekberg, Tobias, von Wachenfeldt, Anna, Azavedo, Edward, Saracco, Ariel, Hellström, Mats, Veerla, Srinivas, Paquet, Eric, Bendahl, Pär‐Ola, Fernö, Mårten, Bergh, Jonas, Loman, Niklas, Hatschek, Thomas, Hedenfalk, Ingrid
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765477/
https://ncbi.nlm.nih.gov/pubmed/28940389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31070
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!